BTA biota holdings limited

biotas open briefing, page-8

  1. TJW
    716 Posts.
    DMA

    Let not ahead of ourselves. I don't believe we can infer that the marketing rights to Relenza is coming back to Biota.

    One thing, Stout said that GSK cannot make money with Relenza, then it would be cheaper to give the marketing rights to Relenza, why hang onto it?

    Cheers
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.